Level of SARS-CoV-2 IgG antibodies after two doses CoronaVac vaccine: Primarily report

Binay, Umut Devrim; Karakeçili, Faruk; Barkay, Orçun; Gül, Özlem; Mertoğlu, Cuma

doi:10.21203/rs.3.rs-388073/v2

Cited by 5 publications

(2 citation statements)

References 3 publications

(3 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The vaccine was first started to be administered to healthcare workers and elderly individuals, and vaccination continued from older individuals to younger individuals gradually. While the pandemic was continuing, the BNT-162b2 (BioNTech) vaccine, which is an mRNA vaccine, has also been started to be used in our country[ 7 , 8 ]. This explains why the average age of those who received two doses of CoronaVac and three doses of vaccine in our study was higher.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of vaccination status on CORADS and computed tomography severity score in hospitalized COVID-19 patients: A retrospective study

Binay,

Karavaş,

Karakeçili

et al. 2023

World J Methodol

View full text Add to dashboard Cite

BACKGROUND The coronavirus disease 2019 (COVID-19) pandemic is continuing. The disease most commonly affects the lungs. Since the beginning of the pandemic thorax computed tomography (CT) has been an indispensable imaging method for diagnosis and follow-up. The disease is tried to be controlled with vaccines. Vaccination reduces the possibility of a severe course of the disease. AIM The aim of this study is to investigate whether the vaccination status of patients hospitalized due to COVID-19 has an effect on the CT severity score (CT-SS) and CORADS score obtained during hospitalization. METHODS The files of patients hospitalized between April 1, 2021 and April 1, 2022 due to COVID-19 were retrospectively reviewed. A total of 224 patients who were older than 18 years of age, whose vaccination status was accessible, whose severe acute respiratory syndrome coronavirus 2 polymerase chain reaction result was positive, and who had a Thorax CT scan during hospitalization were included in the study. RESULTS Among the patients included in the study, 52.2% were female and the mean age was 61.85 years. The patients applied to the hospital on the average 7th day of their complaints. While 63 patients were unvaccinated (Group 1), 20 were vaccinated with a single dose of CoronaVac (Group 2), 24 with a single dose of BioNTech (Group 3), 38 with 2 doses of CoronaVac (Group 4), 40 with 2 doses of BioNTech (Group 5), and 39 with 3 doses of vaccine (2 doses of CoronaVac followed by a single dose of BioNTech, Group 6). CT-SS ranged from 5 to 23, with a mean of 12.17. CT-SS mean of the groups were determined as 14.17, 13.35, 11.58, 10.87, 11.28, 10.85, respectively. Accordingly, as a result of the comparisons between the groups, the CT-SS levels of the unvaccinated patients found to be significantly higher than the other groups. As the vaccination rates increased, the rate of typical COVID-19 findings on CT was found to be significantly lower. CONCLUSION Increased vaccination rates in COVID-19 patients reduce the probability of typical COVID-19 symptoms in the lungs. It also reduces the risk of severe disease and decreases CT Severity Scores. This may lead to a loss of importance of Thorax CT in the diagnosis of COVID-19 pneumonia as the end of the pandemic approaches.

show abstract

Section: Discussionmentioning

confidence: 99%

“…CoronaVac vaccine (Sinovac Life Sciences, Beijing, China), which is an inactive vaccine, has been started to use from the elderly population and healthcare workers in our country as of January 2021[ 7 ]. As of April 2021, the BNT-162b2 (BioNTech/Pfizer) vaccine, which is an mRNA vaccine, has begun to be used[ 8 ].…”

Section: Introductionmentioning

confidence: 99%

Effect of vaccination status on CORADS and computed tomography severity score in hospitalized COVID-19 patients: A retrospective study

Binay,

Karavaş,

Karakeçili

et al. 2023

World J Methodol

View full text Add to dashboard Cite

show abstract

Anti-SARS-CoV-2 spike receptor binding domain (S-RBD) IgG antibodies following CoronaVac administration: a longitudinal study. Anti-SARS-CoV-2 S-RBD IgG antibodies

et al. 2023

View full text Add to dashboard Cite

Reports on antibody titers following CoronaVac administration are still scarce, particularly when it comes to the post-vaccination effectiveness of CoronaVac in the Indonesian population. The purpose of this study is to determine the efficacy of COVID-19 vaccination by comparing the IgG levels against the S1 subunit of SARS-CoV-2 RBD after the first and second vaccinations. The researchers collected venous blood samples from participants after they received the CoronaVac 600 SU/0.5 mL vaccine at two different intervals (14 days and 28 days). Blood was drawn twice (after the first and second vaccinations) and tested for antibodies (positive antibody detection value of 50 AU/mL). Paired data were analyzed by using either the Wilcoxon test (numerical) or the McNemar test (categorical). The median IgG1 levels in the 14-day interval between vaccine doses were 64.40 AU/mL and IgG2 levels were 886.10 AU/mL. Meanwhile, the median IgG1 level was 146.10, and IgG2 level was 688.00.AU/mL in the group with a 28-day interval between vaccine doses. After the first vaccination, 60.00 % of study subjects had positive IgG levels, which increased to 98.57% after the second vaccination. Following the full-dose vaccination, all participants had higher antibody levels, and considered significant. The effect was stronger in the group that received the vaccine at 14-day intervals. CoronaVac has also been shown to increase the prevalence of detectable antibody positivity in study participants.

show abstract

Semi-Quantitative Analysis of Sars-Cov-2 Igg Antibodies Following Chadox1-Ncov (Covishield™) Vaccination

DODDAMANI²,

KISHANRAO³

et al. 2022

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Objectives: The objectives of this study were semi-quantitatively analyze SARS-COV-2 IgG antibodies following covishield vaccination in healthcare workers and to follow-up them for 6 months for persistence of antibodies and for getting infected with SARS-COV-2. Methods: This was a prospective cohort study which was conducted at tertiary care hospital, South India. The blood samples were collected after second dose of vaccine at 28 days, 60 days, and 120 days. The serum was subjected for detection of IgG antibodies against S1 RBD (Receptor binding domain) of the spike protein antigen by Euroimmun kit (PerkinElmer company, Germany) using ELISA. Results: Out of 30 healthcare workers, 28 (93.3%) were seropositive and 2 (6.7%) were seronegative. Out of two seronegative, one participant acquired SARS-COV-2 infection with severe symptoms. There was approximately 50% reduction in antibody levels in almost all seropositive individuals after 3 months of second dose. Even after 6 months, 25 (83.3%) were seropositive, 2 (6.7%) were seronegative, and 3 (10%) were borderline. When the IgG antibody ratio levels of 28 days following second dose of vaccination were compared with levels after 6 months, which showed, p value of 0.024 which is <0.05 implies statistically significant. Conclusion: Covishield vaccine induced good immune response in majority of the participants, the levels were sustainably positive until 6 months but decreasing pattern. The vaccine-induced antibodies prevented the severe symptoms among vaccine breakthrough infections.

show abstract

Level of SARS-CoV-2 IgG antibodies after two doses CoronaVac vaccine: Primarily report

Cited by 5 publications

References 3 publications

Effect of vaccination status on CORADS and computed tomography severity score in hospitalized COVID-19 patients: A retrospective study

Effect of vaccination status on CORADS and computed tomography severity score in hospitalized COVID-19 patients: A retrospective study

Anti-SARS-CoV-2 spike receptor binding domain (S-RBD) IgG antibodies following CoronaVac administration: a longitudinal study. Anti-SARS-CoV-2 S-RBD IgG antibodies

Semi-Quantitative Analysis of Sars-Cov-2 Igg Antibodies Following Chadox1-Ncov (Covishield™) Vaccination

Contact Info

Product

Resources

About